Recent studies examine the burden of CRSwNP, looking at quality of life in patients and caregivers and assessing how CRSwNP ...

Chronic rhinosinusitis with nasal polyps presents a substantial clinical burden, affecting nasal airflow, olfactory function, ...

Patients with chronic rhinosinusitis with nasal polyps saw improvements across all endpoints with tezepelumab, according to ...

In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic ...

Vasomotor rhinitis is a cause of runny nose and congestion not related to allergies or an infection. Learn about the symptoms ...

Shares of OptiNose OPTN soared 52.5% on Thursday after the company announced that it is set to be acquired by Paratek ...

However, the actress also underwent a nose surgery to treat a nasal polyp. There were complications in the surgery which ...

Nasal Polyps Treatment Market Research Report The global nasal polyps treatment market is expected to reach around $4,243.9 million by 2030 ...

Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ...

Silent rhinovirus (RV) infection is prevalent in nasal tissues and is associated with distinct immune responses in those with and without chronic rhinosinusitis with nasal polyps (CRSwNP). These were ...

Cash and cash equivalents as of December 31 were $40.6M compared with cash, cash equivalents and short-term investments of $51.6M at ...